Christopher Peetz, Chief Executive Officer of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), conducted significant transactions involving the company's common stock on June 1, 2026. The CEO sold 30,000 shares, generating total proceeds valued at approximately $2.88 million. These sales followed the initial exercise of options that allowed Mr. Peetz to acquire an equal number of shares.
The context for these transactions is notable given the stock's performance; over the preceding year, Mirum Pharmaceuticals common stock had delivered a 100% return and was trading at $92.17 per share.
Details of the Stock Transactions
The process began with Mr. Peetz exercising employee stock options to obtain 30,000 shares of Mirum Pharmaceuticals common stock. The cost basis for these acquired shares was determined by an exercise price of $2.936 per share, resulting in a total outlay of $88,080. It is noted that these specific options were fully vested.
Immediately subsequent to the option exercise, Mr. Peetz disposed of the 30,000 shares through multiple sales transactions. The selling prices varied across the range of $93.90 to $99.79 per share. Based on a calculation using these varying rates, the weighted average sale price for the shares fell between $94.64 and $99.66. Cumulatively, the total money received from liquidating all these shares amounted to approximately $2,875,103.
Crucially, the article specifies that all sales were executed under a Rule 10b5-1 trading plan, which Mr. Peetz had formally adopted on March 2, 2026.
Current Holdings and Corporate Activity
Following the completion of these recent sales, the article details Mr. Peetz's remaining holdings. He currently holds a direct stake of 194,309 shares of Mirum Pharmaceuticals common stock. Additionally, his indirect ownership is represented by 187,500 shares held through The Peetz Family Trust. Furthermore, he retains options that grant him the right to purchase an additional 128,487 shares of common stock.
Beyond executive movements, Mirum Pharmaceuticals also announced a major financial maneuver: the pricing of $600 million in convertible senior notes due in 2032. These notes carry a stated interest rate of 0.00% and are targeted for qualified institutional buyers. The private placement structure includes an option for initial purchasers to secure an additional $90 million worth of notes.
The company intends to utilize the proceeds from this financing, alongside common stock issuance, to facilitate the exchange of a portion of its existing 4% convertible bonds due in 2029. The remaining funds generated by the placement are designated for general corporate purposes.
Analyst Coverage and Market Outlook
The company's strategic positioning was highlighted by external analysts. Wolfe Research initiated coverage on Mirum Pharmaceuticals with an 'outperform' rating, setting a price target of $145.00. This assessment anticipates that the peak worldwide sales for Livmarli could reach nearly $940 million. Separately, Citizens maintained its 'Market Outperform' rating and reiterated a price target of $140.00, emphasizing the company’s upcoming late-stage clinical readouts.
These combined developments - the corporate financing structure, the optimistic sales projections from analysts, and the ongoing R&D milestones - collectively underscore both Mirum Pharmaceuticals’ strategic financial planning and its anticipated growth trajectory in the pharmaceutical sector. For valuation insights, one source indicated that based on Fair Value metrics, the stock appeared overvalued at current market levels.